Comparative Persistency with Newer agents used to Treat Type 2 Diabetes (T2dm) In the united states- canagliflozin Versus Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors and Glucagon-Like Peptide-1 (Glp-1) agonists
May 1, 2015, 00:00
10.1016/j.jval.2015.03.398
https://www.valueinhealthjournal.com/article/S1098-3015(15)00455-6/fulltext
Title :
Comparative Persistency with Newer agents used to Treat Type 2 Diabetes (T2dm) In the united states- canagliflozin Versus Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors and Glucagon-Like Peptide-1 (Glp-1) agonists
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)00455-6&doi=10.1016/j.jval.2015.03.398
First page :
A68
Section Title :
Diabetes/Endocrine Disorders
Open access? :
No
Section Order :
1499